In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 30, 2020
New Biobanking LIMS Accelerator for Managing COVID-19 Testing
Author(s)BioPharm International Editors
A comprehensive turnkey system based on LabVantage’s laboratory information management system platform allows laboratories to implement COVID-19 biobanking, testing, and research.
Advertisement
LabVantage Solutions, a provider of laboratory informatics solutions and services, developed a new purpose-built COVID-19 laboratory information management system (LIMS) solution. The solution enables laboratories to enter biospecimens into a biobank and rapidly begin COVID-19-related testing and research, the company reported in an April 28, 2020 press release.
The LabVantage COVID-19 Biobanking Accelerator is built on the company’s LIMS and biobanking platforms. The solution is delivered as a comprehensive software-as-a-service (SaaS) solution, requires no infrastructure investment, and is pre-configured, which means minimal implementation time is needed with a go-live start possible in less than four weeks, according to the company.
The accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. The company reports that the solution incorporates multiple protocols defined by the Centers for Disease Control and Prevention for COVID-19 testing and can easily accommodate additional standard and customized protocols for testing using a variety of approaches, such as reverse transcription polymerase chain reaction, isothermal nucleic acid amplification, and serology.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5